European Union Council Backs Pharma Package Setting Nine-Year Medicine Protection

by admin
European Union Council Backs Pharma Package Setting Nine-Year Medicine Protection

European Union governments adopted the Council position on the pharma package on 28 September 2026, setting nine years of baseline protection for new medicines, with a Parliament vote indicatively due on 23 November 2026.

The Council of the European Union adopted its position on the EU "pharma package" on Sept. 28, 2026, approving a new regulation and directive that rewrite the rules for how drug makers develop, authorise and supply human medicines across the bloc1.

In short, the Council has signed off on the biggest change to EU medicines law in 20 years, but the European Parliament must still vote before it becomes law. Once in force, drug companies face shorter default protection from generic competition, new duties to supply every member state and prevent shortages, and new rewards for antibiotics.

The Council’s vote completes its first-reading stage. A European Commission communication dated Sept. 29, 2026, says the Council position "fully reflects" the political deal the Council and Parliament struck on Dec. 11, 2025, and that the Commission can accept it1. Parliament’s public health committee approved the agreed text on March 18, 2026, and the plenary vote is pencilled in for Nov. 23, 20262.

What does the EU pharma package replace?

The package is made up of two laws: a directive on a Union code for human medicines, and a regulation on EU authorisation procedures and the European Medicines Agency (EMA)3. Together they replace four existing acts: Directive 2001/83/EC, Regulation (EC) No 726/2004, the Paediatric Regulation and the Orphan Regulation for rare-disease medicines1.

The new law also makes targeted changes to the rules on advanced therapies, the Clinical Trials Regulation and EMA’s extended mandate4. The Commission first proposed the reform on April 26, 20235. The Commission’s stated aims include faster access to medicines, more innovation, fewer shortages and less paperwork for companies and regulators1.

How long will new medicines be protected from generics?

Two kinds of protection keep cheaper copies off the market. Data protection stops competitors relying on the original maker’s trial data. Market protection stops generic and biosimilar versions from being sold3.

Under the agreed text, a new medicine gets a nine-year baseline protection: eight years of data protection and one year of market protection1. Companies can earn extra time in several ways:

  • one more year of market protection for a medicine that meets an unmet medical need;
  • or one more year for a new active substance tested against existing treatments in clinical trials, combined with trials in several EU countries or an early EU application;
  • one year for a new use that brings significant clinical benefit.

The first two routes are alternatives, granted at the time of first approval1. Total protection is capped at 11 years3.

How do the rules change for rare-disease medicines?

Medicines for rare diseases, known as orphan medicines, get nine years of market exclusivity, a period during which similar products cannot be approved1. "Breakthrough" orphans earn two more years. These are medicines for conditions with no other treatment that clinically reduce illness or death among patients1.

Protection periods under the pharma package

QuestionNew medicinesOrphan medicines
Baseline8 years data plus 1 year market protection9 years market exclusivity
Main extra time1 year for unmet need or comparative trials2 years for breakthrough orphans
Maximum11 years13 years

A further year is available, up to twice, for new uses in a different rare condition. All the extra years together cap orphan exclusivity at a maximum of 13 years1.

What do companies get for new antibiotics?

The package creates a transferable exclusivity voucher, a reward for developing a new "priority antimicrobial," a medicine needed to fight drug-resistant infections1. The voucher grants one extra year of data protection. The company can apply it to the antimicrobial itself or, under conditions, transfer it to another medicine1.

Two limits apply. The voucher cannot be used on a product with annual gross sales over EUR 490 million in any of its first four years after approval1. And the company must file its EU application within 180 days of its first application outside the EU1.

Member states may also buy antimicrobials jointly under a voluntary "subscription model," which pays developers steady revenue1. All antimicrobials will need a prescription, and patient leaflets must carry specific information3.

What must drug makers do on supply and shortages?

Member states may require the holder of a marketing authorisation, the company licensed to sell a medicine, to take specific steps to supply it1. The aim is enough continuous supply to meet patients’ needs in every member state concerned1.

Companies must notify supply disruptions six months ahead, and national regulators will monitor expected and actual shortages1. Shortage prevention plans become mandatory six months after the regulation enters into force. They cover prescription medicines and certain medicines the Commission identifies1.

Generic and biosimilar makers gain from a wider Bolar exemption, the rule that lets them test copies before the original patent expires1. They may now also seek pricing, reimbursement and health technology assessment decisions, and join public tenders, while the patent still runs. This lets generics launch on day one after protection ends1.

What else changes at EMA and for companies?

EMA’s scientific committees will be simplified and reduced in number. The standard assessment time for a medicine falls from 210 days to 180 days1.

Standard EMA assessment time, days

Current 210 days
Under the package 180 days

Companies must publicly declare any direct financial support from public bodies, charities or non-profit funds1. Environmental risk assessments for antimicrobials must now cover manufacturing1. Rules on abortion drugs and contraceptives stay unchanged, and restricting them remains a national matter1.

When will the EU medicines rules apply?

Member states have 24 months to transpose the directive into national law, and the regulation applies on the same timetable1. EMA describes the period up to 2028 as a transition, during which the Commission, EMA and national regulators will issue implementation guidance4.

Road to the new medicines law

11 Dec 2025 Council and Parliament deal
28 Sep 2026 Council adopts position
23 Nov 2026 Indicative Parliament vote

Some parts start earlier. The antibiotic voucher, regulatory sandboxes and subscription model guidelines apply from entry into force1. Member states may apply the access rules 12 months after the directive enters into force, and electronic product information applies six months before the general date1. The next step is Parliament’s plenary vote, indicatively set for Nov. 23, 20262.

Sources

  1. ↩ EUR-Lex – 52026PC0527 – EN – EUR-Lex https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2026&nu_doc=0527
  2. ↩ Procedure File: 2023/0131(COD) | Legislative Observatory | European Parliament https://oeil.secure.europarl.europa.eu/oeil/en/procedure-file?reference=2023/0131(COD)
  3. ↩ Carriages preview | Legislative Train Schedule https://www.europarl.europa.eu/legislative-train/spotlight-JD%2023-24/file-revision-of-the-pharmaceutical-legislation
  4. ↩ Reform of the EU pharmaceutical legislation | European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/what-we-do/reform-eu-pharmaceutical-legislation
  5. ↩ Reform of EU pharmaceutical legislation – Public Health https://health.ec.europa.eu/medicinal-products/reform-eu-pharmaceutical-legislation_en

You may also like